Incyte beats on earnings, revenue–but drops on lack of improved guidance
Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings...
Analyst upgrade is catalyst for 6.17% jump in Acadia Pharmaceuticals today
 Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock...
4th pick for Special Report 10 Stocks to Beat Amazon–SGEN
My fourth pick in my Special Report "10 Stocks to Beat Amazon" is a biotech, Seattle Genetics (SGEN). Biotech companies spend years developing their first successful drug. And then spend more years turning that first drug into a pipeline of drugs and expanded labels....
Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months
I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don't think the gods of investing have repealed the laws of valuation. At some...
Trump administration picks five coronavirus vaccine efforts to receive big government funding
The Trump administration has identified five companies that will get major government funding for the development of a coronavirus vaccine under Operation Warp Speed, the New York Times reported yesterday. The White House is expected to officially announce the names...
Stock Pick of the Day: Acadia Pharmaceuticals (ACAD)
As I wrote in my previous post this morning, I like the upward momentum in the biotech sector resulting from the race for a coronavirus vaccine and treatment and the cash flows into the sector from investors and big drug companies such as Pfizer (PFE.) That has pushed...
More headroom for biotech sector–and heads up on a coming pick
On May 29 the iShares NASDAQ Biotechnology ETF (IBB) hit an all-time high of $134.85, breaking the record of $133 set in 2015. Not surprising with money flooding into the sector as everyone and their Aunt Sally looks to find the stock that will rocket to the moon on...
Still selling Intrexon (now Precigen) even though the 293% gain yesterday wasn’t real
Frankly, my first reaction was to think it was a misprint, especially because while the ticker still read XON, the name of the attached stock had changed from Intrexon to Precigen. And it was. A misprint, that is. The print yesterday showed that the stock, a member of...
Selling Intrexon (now Precigen) after 293% gain today
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness
Yesterday an advisory joint committee at the U.S. Food & Drug Administration voted to reject Nektar's application for its new non-addictive opioid NKTR-181. The thinking--my thinking--was that the committee had structured the vote so that the most likely outcome...
Nektar’s new non-addictive opioid NKTR-181 to finally get an FDA advisory vote tomorrow
I understand why the U.S. Food & Drug Administration has moved so slowly on a decision on Nektar Therapeutic's (NKTR) new non-addictive opioid NKTR-181. The last thing the FDA wants to do in the midst of epidemic of opioid addiction is to approve a drug that might...Download Jim’s eBook for Free
